Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lutetium Lu 177-DOTA-ABM-5G

A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[177Lu]-DOTA-ABM-5G
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search